- Home
- WINT vs WORX Comparison
WINT vs WORX Comparison
Compare WINT & WORX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- WINT
- WORX
- Stock Information
- Founded
- WINT 1992
- WORX N/A
- Country
- WINT United States
- WORX United States
- Employees
- WINT N/A
- WORX N/A
- Industry
- WINT Biotechnology: Biological Products (No Diagnostic Substances)
- WORX Services-Misc. Amusement & Recreation
- Sector
- WINT Health Care
- WORX Consumer Discretionary
- Exchange
- WINT Nasdaq
- WORX Nasdaq
- Market Cap
- WINT 1.5M
- WORX N/A
- IPO Year
- WINT 1995
- WORX N/A
- Fundamental
- Price
- WINT $1.20
- WORX $0.66
- Analyst Decision
- WINT Hold
- WORX
- Analyst Count
- WINT 1
- WORX 0
- Target Price
- WINT $350.00
- WORX N/A
- AVG Volume (30 Days)
- WINT 7.7M
- WORX 31.3K
- Earning Date
- WINT 04-15-2025
- WORX 05-09-2025
- Dividend Yield
- WINT N/A
- WORX N/A
- EPS Growth
- WINT N/A
- WORX N/A
- EPS
- WINT N/A
- WORX N/A
- Revenue
- WINT N/A
- WORX $2,989,599.00
- Revenue This Year
- WINT N/A
- WORX N/A
- Revenue Next Year
- WINT N/A
- WORX N/A
- P/E Ratio
- WINT N/A
- WORX N/A
- Revenue Growth
- WINT N/A
- WORX N/A
- 52 Week Low
- WINT $1.10
- WORX $0.61
- 52 Week High
- WINT $737.50
- WORX $4.44
- Technical
- Relative Strength Index (RSI)
- WINT 27.23
- WORX 30.78
- Support Level
- WINT $1.22
- WORX $0.67
- Resistance Level
- WINT $2.17
- WORX $0.79
- Average True Range (ATR)
- WINT 0.32
- WORX 0.05
- MACD
- WINT 0.20
- WORX 0.02
- Stochastic Oscillator
- WINT 3.54
- WORX 9.03
About WINT Windtree Therapeutics Inc.
Windtree Therapeutics Inc is a biotechnology company focused on advancing early and late-stage innovative therapies for critical conditions and diseases. Its portfolio of product candidates includes istaroxime, a Phase 2 candidate with sarco endoplasmic reticulum Ca2+ -ATPase 2a, or SERCA2a, activating properties for acute heart failure and associated cardiogenic shock, preclinical SERCA2a activators for heart failure, rostafuroxin for the treatment of hypertension in patients with a specific genetic profile, and a preclinical atypical protein kinase C iota, or aPKCi, inhibitor, being developed for potential application in rare and broad oncology indications. It operates in one operating segment, which is the research and development of products focused on cardiovascular disease.